.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Managing glycemic control remains a significant challenge for many individuals with advanced type 2 diabetes. While injectable GLP-1 receptor agonists are highly effective, many patients prefer oral alternatives. Orforglipron for Type 2 Diabetes represents a major shift in treatment, as it is a nonpeptide, small-molecule agonist that can be taken once daily without the strict fasting requirements associated with some other oral agents. The recently published ACHIEVE-5 trial investigated whether adding orforglipron to titrated insulin glargine could further optimize blood glucose levels and metabolic health.
The phase 3 ACHIEVE-5 study enrolled 546 adults who were already using insulin glargine but had inadequate glycemic control. Researchers randomized participants to receive either a placebo or one of three daily dosages of orforglipron: 3 mg, 12 mg, or 36 mg. After 40 weeks, the results were statistically significant. Specifically, participants taking orforglipron achieved mean HbA1c reductions between -1.58% and -1.88%, compared to just -0.79% in the placebo group. Furthermore, a substantially higher percentage of those in the orforglipron group reached the target HbA1c of less than 7.0%.
Beyond glycemic control, the trial highlighted impressive weight loss outcomes. Participants receiving the 36-mg dose experienced a mean body weight change of -8.41%, whereas the placebo group saw a slight weight increase of 0.60%. This weight-neutral or weight-reducing effect is particularly beneficial for patients on insulin therapy, which is often associated with weight gain. Additionally, orforglipron demonstrated a manageable safety profile. Although gastrointestinal side effects like nausea and diarrhea were more common in the orforglipron arms, most cases were mild to moderate. These events typically occurred during the initial dose-escalation phase and decreased over time.
Hypoglycemia is a major concern when adding new agents to insulin. However, the ACHIEVE-5 trial found that rates of clinically significant hypoglycemia (level 2 or 3) were generally similar between the orforglipron and placebo groups. This suggests that orforglipron can be safely integrated into complex insulin regimens. Consequently, this oral option may provide a viable alternative for patients who have reached their limit with injectable therapies but still require additional metabolic support.
Orforglipron is a nonpeptide, small-molecule agonist. Unlike peptide-based GLP-1s like semaglutide, orforglipron is not easily degraded by stomach acid and does not require complex oral delivery technologies or strict fasting before administration.
The most common side effects were gastrointestinal, including nausea, vomiting, and diarrhea. These symptoms were dose-dependent and typically occurred during the early stages of treatment titration.
Yes. In the ACHIEVE-5 trial, the highest dose of orforglipron led to an average weight loss of approximately 8.4% over 40 weeks, which is a significant benefit for patients with type 2 diabetes and obesity.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Giorgino F et al. Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial. JAMA. 2026 Jun 07. doi: 10.1001/jama.2026.9512. PMID: 42251769.
Frias JP et al. Orforglipron for the Treatment of Type 2 Diabetes. New England Journal of Medicine. 2023;389(10):896-907.
Wharton S et al. Daily Oral Orforglipron for Adults with Obesity. New England Journal of Medicine. 2023;389(10):877-888.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The ACHIEVE-5 trial demonstrates that orforglipron significantly reduces HbA1c and body weight in type 2 diabetes patients using insulin glargine....
last month
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
